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Sherry Glied, PhD,1 Steven M. Teutsch, MD, MPH2,3,4The British economist Lionel Robbins oncedescribed economics as the study of “humanbehaviour as a relationship between ends and
scarce means which have alternative uses.”1 Those “ends”
include health and those “means”—woefully scarce—
include the money and time of public health departments
as well as of the populations they serve. Public health and
prevention policymakers are endlessly engaged in choos-
ing among the alternative uses to which these scarce
resources must be put. Economists can help them make
those choices, and economic insights can, thus, increase
the level of population health generated with those scarce
resources. Below, the authors discuss ways that economic
analysis is used in public health and prevention policy-
making, and ways that these analyses could be more
effective in the policymaking process.
Economics can contribute to wise population health
policymaking in several ways. Most obviously, economists
can formally model the costs and beneﬁts of alternative
prevention policies at the societal level. Economic assessments
of societal costs and beneﬁts are likely to be most persuasive
when they directly consider alternative choices for deploying
resources. Resources of all sorts, including the time and
attention of policymakers, are in short supply. Many
preventive interventions meet standard cost–beneﬁt criteria,
but policymakers cannot pursue them all and must prioritize.
Economic research may lead to change more effectively if it is
explicit about the opportunity costs for society and different
stakeholders of choosing one path over another. The U.S.
Food and Drug Administration’s decision to fortify cereal
grains with folic acid rather than relying on education and
supplementation was informed by an economic evaluation
formally comparing these speciﬁc options.2
Health economists often conduct cost-effectiveness
analyses, which are useful in assessing the relative
merits of different health-related programs. Formalobert F. Wagner Graduate School of Public Service, New York
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tangible and intangible beneﬁts, can also be used to
compare health and non-health programs. Economic
methods for monetizing non-tangible beneﬁts are
widely used in other arenas. For example, economic
analyses of environmental policies consider the intan-
gible beneﬁts people obtain from green space and parks,
the costs of pollution on health, and the costs of
rising temperatures on productivity3–5 For example,
the Washington State Institute for Public Policy has
conducted cost–beneﬁt analyses of many prevention
programs, allowing policymakers to compare them
directly to non-health programs (for example, www.
wsipp.wa.gov/BeneﬁtCost/Program/412).
Most economic research in public health and prevention
has consisted of analyses of this type—assessing the societal
cost effectiveness of alternate strategies. Economic theory,
codiﬁed in the work of the Panel on Cost Effectiveness in
Health and Medicine, clearly indicates that the societal
perspective is indeed the right one to consider in comparing
and assessing policies.6 The societal perspective recognizes
that most policies generate both beneﬁts and costs, winners
and losers. An intervention that is socially cost beneﬁcial is
one where the beneﬁts exceed the costs, where the winners
could (hypothetically) fully compensate the losers. But
economic analyses in public health and prevention could
be even more powerful by recalling other fundamental
disciplinary insights. Economics recognizes that human
behavior, in balancing ends and means, depends not (only)
on the societal good but also on the incentives facing each
speciﬁc actor. Economists can play a valuable role in
decomposing the costs and beneﬁts of alternative actions
among actors. Decomposing societal gains among winners
and losers yields insights into choices among priorities and
among methods. A government agency may choose not to
pursue a highly societally beneﬁcial intervention if the costs
will be incurred in its budget while the savings accrue to a
different agency. A recent analysis of how free transit passes
could increase school attendance and graduation rates
illustrates how trade-offs between expenses borne by a
transit agency could be offset by income from increased
school attendance.7
The potential mismatch between societal beneﬁts and
individual incentives suggests three further steps. First,
economists can help lay out the business case for a practice
for each of the key players. For example, HealthPartners, a
Minnesota-based health plan, built a business case foral of Preventive Medicine  Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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including improving the social and physical environments.8
Second, economic analysis can provide information about
the size and direction of cross-agency or actor payments
that might be needed to compensate losers.7 These pay-
ments might take the form of budget adjustments across
agencies, or of subsidies or taxes in the private sector. Third,
this decomposition also reveals the incentives facing
different actors in the system and may lead to changes in
the design of these incentives.
Economic analysis of policy often focuses on the
design of incentives. Economic research examines how
changes in prices—for example, taxes on cigarettes—
lead to changes in behavior by altering the incentives
faced by purchasers. Most recently, a new branch of
economic research, behavioral economics, has inte-
grated insights from psychology into this focus on
incentives. By taking into account the way people
consider wins compared with losses, how they deal with
active compared to passive decisions, and how they
prioritize or procrastinate over time, behavioral eco-
nomics has led to improvements in the design of
incentives to lose weight and quit smoking. Incorporat-
ing a behavioral economics approach into prevention
policymaking may allow policymakers to generate more
beneﬁt with the same cost.9–11
Finally, economics can also contribute to public health and
prevention by pushing the empirical basis of decisionmaking
forward. Economic policy, like public health policy, addresses
the behavior of populations and the complex interactions of
programs, policies, and systems that affect health.
Population-oriented policies, systems, and programs exist
within complex social contexts, making them challenging to
evaluate through the RCTmethods that are the gold standard
of medical research. Economics has reﬁned an extensive
toolkit of methods for evaluating them without RCTs. These
methods include an array of quasi-experimental methods
(often borrowed from epidemiology) that can be used to
draw causal inferences about policies in situations where it
would be difﬁcult to design and implement ethical, general-
izable, large-scale trials.12 Economists working in public
health and prevention have also contributed to the design
of simulation models. Well-designed simulation models can
be used to forecast the implications for costs and beneﬁts of
changes in policy, where the empirical evidence base is
limited to surrogate endpoints. Prevention Impacts Simula-
tion Model for Chronic Disease Policymaking, for example,
is a practical tool for communities and decision makers to
assess the health impacts and costs of clinical, behavioral,
social, and environmental interventions to reduce cardiovas-
cular disease.13
As public health returns to its historic roots and increas-
ingly addresses the socioeconomic and environmentalMay 2016determinants of health and health disparities, economic
tools can play a critical role in identifying and choosing
effective and cost-effective strategies to tackle some of
society’s most fundamental problems. Even within the
medical model of public health practice, the need to
understand health and healthcare systems and how best to
allocate scarce resources requires economists to apply the
full range of their methods and skills to assure scarce
resources are used wisely.
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